New data on the COVID-19 antibody therapy Ronapreve (casirivimab + imdevimab), already used to treat non-hospitalized patients in multiple countries, could potentially support expanding its use to certain recently hospitalized patients with the disease.
With fresh funds and a pivotal trial underway, Sommetrics Inc. may be about to shed its sleeper status. Executives at the Vista, Calif.-based company hope to provide a quiet, effective solution to obstructive sleep apnea (OSA) that’s less obtrusive and better tolerated than the continuous positive airway pressure (CPAP) machines that currently dominate the market.
LONDON – A large-scale analysis of U.S. data shows that 57% of patients with a recorded diagnosis of COVID-19 subsequently presented to their physicians with symptom(s) of long COVID. In 37% of those patients, the symptoms were not reported until three to six months after they contracted COVID-19, indicating they are not persisting acute symptoms.
LONDON – Industry-sponsored clinical research in the U.K. took a big hit in the pandemic and is still struggling to catch up – and to capitalize on innovative trial designs and delivery approaches that were so successful in speeding up COVID-19 studies.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Altimmune, Artios, Dicerna, Ena Respiratory, First Wave, Graybug, Mind Medicine, Oncoinvent, Pfizer, Sanofi, Seagen, Translate, Valneva.
LONDON – A large-scale analysis of U.S. data shows that 57% of patients with a recorded diagnosis of COVID-19 subsequently presented to their physicians with symptom(s) of long COVID.
Now that Pfizer Inc.-Biontech SE has submitted initial phase II/III study data to the FDA bolstering the case for an emergency use authorization (EUA) for its COVID-19 vaccine to children ages 5 through 11 years, the competition, including Moderna Inc., Novavax Inc. and Sanofi SA, falls further behind.
Cstone Pharmaceuticals Co. Ltd. released positive data from the phase III trial, Gemstone-302, of sugemalimab plus chemotherapy for the first-line treatment of patients with stage IV squamous and non-squamous non-small cell lung cancer.
Imugene Ltd.’s recent win with a patent granted in Japan with its HER-Vaxx immunotherapy, in development for HER2-positive gastric cancer, represented a smallish but significant win in the HER2/neu space, where plenty of other players are busy, with Greenwich Life Sciences Inc. a strong emerging name.
RSS
